“The sale of this voucher is a prime example of our double bottom line model at work, as it not only enables us to provide substantial returns for our investors, but it also fulfills our mission of improving lives in low-income countries by greatly bolstering efforts to eliminate river blindness,”
said Curt LaBelle, MD, Managing Partner of the Global Health Investment Fund.
The FDA’s neglected tropical disease PRV program is designed to encourage the development of drugs and treatments for rare and neglected diseases. Upon approval of a new treatment for a listed neglected disease, the developer receives a voucher to receive a priority review for another product from the FDA. This priority review shortens the review of a new drug application to six months rather from ten or more. The voucher can be sold, without restrictions, to third parties.
“We are delighted to have achieved this key milestone in the moxidectin story, a medicine that would have been left on the shelf without GHIF and the PRV funding mechanism,”
said Mark Sullivan, Managing Director of MDGH.
“For those who believed in moxidectin and in us, this is further endorsement for that valuable support. Ultimately, we are all doing this for the communities affected by river blindness and other neglected diseases and we look forward to working towards further development and delivery of this medicine. We particularly acknowledge the FDA for putting the PRV mechanism in place.”
MDGH was the first non-profit company to be awarded a priority review voucher by the FDA, and moxidectin is the first new FDA-approved treatment for river blindness in the last 20 years.
Jefferies LLC acted as exclusive financial advisor to Medicines Development for Global Health on this transaction.